SS-31 benefits include better mitochondrial energy output and less oxidative stress. Learn what elamipretide research shows, dosing, and safety.
SS-31 (elamipretide) is a synthetic tetrapeptide that binds to cardiolipin on the inner mitochondrial membrane, and the SS-31 benefits most often reported in research are higher mitochondrial energy output, reduced oxidative stress, and better function in tissues that burn a lot of energy, such as heart muscle, skeletal muscle, and the retina. Those effects have been measured in laboratory studies, animal models, and small human trials, but larger clinical trials have produced mixed results, and the FDA has not approved SS-31 for any human use.
If you have seen SS-31 described as a "mitochondrial rescue" peptide, this article explains what the evidence actually supports, what it does not, and what researchers still do not know.
What SS-31 Is and How It Works
SS-31 is a four-amino-acid peptide (D-Arg-Dmt-Lys-Phe-NH2) designed to target mitochondria directly instead of acting on receptors elsewhere in the body. It concentrates inside cells and binds cardiolipin, a phospholipid that helps shape the inner mitochondrial membrane and keep the electron transport chain organized.
By stabilizing cardiolipin, SS-31 appears to help mitochondria produce ATP more efficiently while leaking fewer reactive oxygen species. That mechanism is why it is usually described as a mitochondria-targeted antioxidant rather than a general antioxidant. Elamipretide is the clinical name used in human trials; SS-31 is the research name used in most preclinical literature.
SS-31 Benefits Reported in Research
Preclinical studies have explored a broad range of potential SS-31 benefits. The strongest signals cluster around tissues that depend heavily on mitochondrial ATP.
- Energy metabolism: Animal and cell studies report improved ATP production and better mitochondrial efficiency after SS-31 exposure.
- Oxidative stress: SS-31 has been shown to reduce markers of reactive oxygen species damage in heart, kidney, and nerve tissue.
- Cardiac function: Rodent models of heart failure and ischemia-reperfusion injury show improved contractile performance and smaller infarct size.
- Muscle performance and fatigue: Animal studies suggest better exercise tolerance and less fatigue-related decline in mitochondrial function.
- Vision and retina: Retinal cells are extremely energy-demanding, and SS-31 has been studied for protection against age-related retinal degeneration in animals.
- Kidney and nerve tissue: Early research has looked at protection against acute kidney injury and neurodegeneration in animal models.
Most of these findings come from animal models, and animal results do not always translate into human benefit. Positive results in mice are a starting point for research, not proof of a clinical effect.
What Human Clinical Trials Actually Show
Human data on SS-31 is thinner and less consistent than the animal data. Several late-stage trials in mitochondrial and age-related conditions missed their primary endpoints, while secondary measures sometimes suggested a signal.
| Condition studied | Reported outcome | Status |
|---|---|---|
| Barth syndrome | Improvements reported in some functional measures; FDA issued a complete response letter | Not approved |
| Primary mitochondrial myopathy | Phase 3 trial did not meet its primary endpoint | Not approved |
| Dry age-related macular degeneration | Phase 2 trial missed its primary endpoint; exploratory measures showed mixed results | Not approved |
| Heart failure | Small early studies showed hemodynamic changes; larger trials not completed for approval | Investigational |
Elamipretide has not been approved by the FDA for any indication. Some trials showed improvements in secondary or exploratory measures, but regulators have not accepted those results as proof of clinical benefit.
That gap matters when evaluating SS-31 benefits. A measurable change in a lab marker is not the same as a benefit a patient can feel or a doctor can prescribe.
SS-31 vs. MOTS-c: How They Compare
Researchers often compare ss-31 and mots-c because both are mitochondria-focused peptides, even though they work in very different ways. SS-31 is a synthetic cardiolipin-binding peptide, while MOTS-c is a naturally occurring mitochondrial-derived peptide that influences metabolic signaling.
| Feature | SS-31 (elamipretide) | MOTS-c |
|---|---|---|
| Origin | Synthetic tetrapeptide | Endogenous mitochondrial-derived peptide |
| Primary target | Cardiolipin on inner mitochondrial membrane | AMPK-related metabolic pathways |
| Main research interest | Oxidative stress, cardiac and muscle function | Insulin sensitivity, metabolic stress, exercise response |
| Routes studied | Subcutaneous injection, intravenous infusion | Subcutaneous injection in animal studies |
| FDA status | Not approved for human use | Not approved for human use |
Some experimental protocols pair ss-31 and mots-c together in the belief that one supports mitochondrial structure while the other supports metabolic signaling. There is no published human trial data on combining these peptides, so any stacked protocol is speculative.
SS-31 Dosing Used in Research
Dosing varies widely between studies, and no human dose has been established as safe or effective. Most published work on ss-31 peptide dosing falls into a few ranges:
- Animal studies: typically 1 to 5 mg/kg per day, often given by injection.
- Human subcutaneous trials: most commonly 40 mg once daily.
- Earlier heart-failure studies: intravenous infusions rather than daily injections.
Discussions of ss-31 dosage reddit threads and forum posts often cite numbers that do not match any published trial. Anyone considering a research peptide should treat online dosing claims with caution and speak with a licensed healthcare professional first.
Safety, Side Effects, and Sourcing
In clinical trials, reported ss 31 side effects were generally mild and included injection site reactions, headache, nausea, and dizziness. Serious adverse events were uncommon, but long-term safety in healthy adults has not been studied.
SS-31 sold as a research chemical is not manufactured under FDA oversight for human use. Purity, sterility, and actual peptide content can vary significantly between suppliers, and a certificate of analysis is only as reliable as the lab that issued it.
People who search for where to buy ss-31 peptide or try to ss-31 peptide buy online usa often end up with products labeled "for research use only." Buying a research chemical does not make it safe for injection, and unverified sources carry real risks of contamination and dosing error.
The Bottom Line
The most credible SS-31 benefits come from its mitochondrial mechanism: better ATP efficiency, less oxidative damage, and improved function in high-energy tissues in animal models. Human trials have not yet confirmed a clear clinical benefit, and the FDA has not approved elamipretide for any condition.
SS-31 remains an investigational peptide with real scientific interest and unresolved questions. Anyone weighing its use should consult a physician, review the primary literature rather than forum posts, and treat marketing claims as unproven until stronger human data exists.
Frequently Asked Questions
Is SS-31 approved by the FDA?
No. Elamipretide, the clinical form of SS-31, has not received FDA approval for any indication. The agency issued a complete response letter for Barth syndrome, and a Phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoint. Products sold online are research chemicals, not approved medications.
What is SS-31 used for in research?
Researchers study SS-31 for its effects on mitochondrial function, including oxidative stress, cardiac performance, muscle fatigue, retinal health, and kidney injury. Most of that evidence comes from cell and animal models. Human trials have focused on Barth syndrome, primary mitochondrial myopathy, dry age-related macular degeneration, and heart failure.
What are the side effects of SS-31?
In human trials, the most common side effects were mild and included injection site reactions, headache, nausea, and dizziness. Long-term safety in healthy adults has not been established. Anyone considering SS-31 should discuss it with a licensed healthcare professional before use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.